BioSpectrum Asia June 2018 
ROBOTICS AND AI - FACE OF NEW HEALTH

Information technology development in healthcare has been rapidly moving from products to services to solutions. The present decade is one of medical platforms focused on real-time, outcome-based care. The next decade is moving towards medical solutions – using Artificial intelligence (AI), robotics, and virtual and augmented reality – to deliver intelligent solutions for both evidence- and outcome-based health and focusing on collaborative, preventative care. This drastic confluence is leading to AI and robotics defining the face of new health.

2025 Trends 
Buoying Boom 
Phase in APAC
 Like many industries, life sciences, too, faced numerous challenges in 2024, such as a 
slowing economy, and geopolitical conflicts. Despite these headwinds, the sector has 
shown remarkable resilience, with strong prospects for recovery and growth. Significant 
investments are being directed toward research and development in key areas such as 
Antibody Drug Conjugates (ADCs), Cell and Gene Therapies, Artificial Intelligence (AI) and 
Contract Development and Manufacturing Organisations (CDMOs) and many more. These 
f
 ields have been major drivers of growth this year and offer promising opportunities. It’s 
that time of year again when we interact with leaders from major market segments of the 
industry. These leaders provide their insights into what the coming year is likely to hold for 
their respective fields. Lets look into a few trends from life sciences that are expected to 
make a significant splash in 2025

APAC Bullish on Biosupplier Revenue  
Amidst Global Uncertainty The Asia-Pacific (APAC) market plays a 
crucial role for global biosupplier companies, contributing anywhere from 15 per cent to 25 per cent of their total global revenues. Between 2021  and 2023, the bioprocessing market was one of the strongest performers, growing at about 18 per cent  annually due to COVID-19-driven demand. However,2023 was a challenging year for biosuppliers, with  the decline in COVID-19-related spending and various global events impacting business, resulting  in plummeting revenue for most firms.
While the bioprocessing sector saw impressive growth between 2021 and 2022, post-COVID-19 normalisation and rising financing costs have led to  flat growth from 2022 to 2023. Despite this, the market is expected to rebound over the next two years, with an average growth forecast of around 9 per cent from 2023 to 2027, according to a report from Clearstate.

How  alarming is Monkeypox Threat Perception?
As the world finally emerges from the grip of COVID-19, a new threat looms: Mpox 
(formerly known as Monkeypox). In August 2024, the World Health Organisation (WHO) declared Mpox a global health emergency due to the rising cases of the new strain, clade I Mpox in Africa and Sweden, underscoring the urgent need for coordinated global action to monitor and contain the virus. As of September 2024, 2082 confirmed Mpox cases were reported globally, marking the highest number of monthly cases globally since November 2022. Nearly 400 cases have been reported in Asia Pacific this year.How are Asia Pacific countries stepping up surveillance measures and preparing their healthcare systems to combat Mpox? And just how significant is the threat posed by this outbreak?

Rebooting Japan’s Biotech Growth Engine
Japan was once a global leader in life sciences innovation, responsible for nearly 30 per cent of all new drugs. However, its share has since dropped to less than 10 per cent. Between 1995 and 2018, Japan's contribution to the global pharmaceutical industry's valueadded declined by 70 per cent, from 18.5 to 5.5 per cent. Factors such  as strict price controls, reduced government investment in basic research, weak collaboration between industry and universities, and a slow regulatory process have significantly contributed to the decline in Japan's biopharmaceutical competitiveness, as noted in a 2022 paper by the Centre for Life Sciences 
Innovation, part of the Information Technology and Innovation Foundation, US. Japanese companies’ share of clinical trials also declined from 11 per cent in 2013 to 4 per cent in 2023. An IQVIA report found that the number of trials initiated by Japanese companies dropped from 501 in 2013 to 244 a decade later. Additionally, Japan launched only 20 new medicines in 2023, the lowest total since 2014, trailing behind the US and other major markets. Recognising this, the Japanese government 
has announced several initiatives designed to reshape the country’s biopharma ecosystem. These efforts include substantial increases in capital for venture funds, 
targeted subsidies for therapeutic drug development, and a suite of tax incentives aimed at empowering investors, entrepreneurs, and startup employees.

Addressing Root Causes of Brain Disorders with Innovative Therapeutics 

Neuroscience is a complex market encompassing a range of neurological conditions. Drug research and development for diseases related to the nervous system has always been challenging. While the oncology sector has seen remarkable progress with new therapies, neuroscience has historically lagged in providing effective cures or treatments for symptoms. However, there is now promising progress in understanding the intricate biology of these conditions and identifying new drug targets. A wave of novel late-stage candidates is advancing through the development pipeline, offering hope for treating serious Central Nervous System (CNS) disorders and entering the market. Recent high-profile approvals, such as Eisai's Leqembi for Alzheimer’s and Eli Lilly's Kisunla (donanemab-azbt) for the same condition, have significantly bolstered the morale of firms dedicated to developing neurological treatments. The neuroscience sector is suddenly back in action, with pharma companies renewing their interest, spurred by recent US FDA approvals in neurodegenerative diseases like Alzheimer’s. This renewed focus has catapulted neuroscience into one of the most sought-after areas.

Innovation Takes Centre Stage in Paediatric healthcare
Children represent approximately one-third of the world's population, with over 580 million  in the East Asia and Pacific region alone (Source: UNICEF). Historically underrepresented in healthcare care delivery and innovation, the landscape is evolving as governments and healthcare organisations in the region strive to address paediatric healthcare needs. Paediatric healthcare spans recommended immunisations before adulthood to developmental health, mental health, neonatal care and rare diseases, among others. Let’s deep dive into the innovations enhancing children’s well being in the region.

IPO FEVER GRIPS BIOTECH  INDUSTRY
After two tumultuous years marred by geopolitical tensions and recession, the biotech 
sector IPOs (initial public offering) is showing signs of recovery. Experts are hopeful 
that this year will revive the public equity markets for biotech companies. Twelve 
biotech companies have gone public this year, raising a total of nearly $1.5 billion, 
compared to a total of only nineteen biotech companies, throughout 2023. Are biotech IPOs poised for an upswing? Is the worst finally over for biotech IPOs? Let's find out.

What’s APAC’s Recipe of Success in CLINICAL TRIALS MARKET?
Asia-Pacific (APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world (RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

Addressing Accessibility and Affordability of CELL & GENE THERAPIES 
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a 
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s  NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising  growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
We are celebrating International Women's Day this time around by spotlighting women's roles and challenges in life sciences, spanning leadership, clinical trials participation and pay parity issues. Section I of the story highlights remarkable women leading public sector organisations in life sciences in APAC. Section II discusses the persistent issue of pay parity in the sector, while the final section tackles issues related to women in clinical trials. Let's delve deeper.

Next-Gen ADCs as Precision Weapon Against Cancer
Antibody-Drug Conjugates (ADCs) are emerging as a crucial frontier in targeted cancer care. Although the first ADC was approved in 2000, the space has experienced a renaissance in recent times. Major pharmaceutical players like Novartis and Pfizer, including startups, are announcing deals in this space almost every day. Within the Asia-Pacific (APAC) region, China stands at the forefront of ADC drug development. GlobalData reports that numerous domestic companies in China are actively shifting their focus towards the creation of pioneering ADC-based treatment options, particularly for solid tumours like breast, gastric, and bladder
cancer. When we observe World Cancer Day on February 4, we explore the promising world of next-gen ADCs, exploring advancements and unravelling the advantages they offer compared to other therapies like cell and gene therapies.

Transformative Life Sciences Trends for 2024
The intersection of tech and healthcare holds immense potential for the life sciences industry. From generative artificial intelligence (GenAI), augmented reality (AR), and virtual reality (VR) to decentralised clinical trials and 3D printing, we delve into the latest tech trends such Cellular Multi-Omics, Gene Editing CRISPR Technologies, Decentralised Clinical Trial (DCTs), digital health, digital twins, smart manufacturing, and wearables poised to lead the life sciences landscape in 2024.

Buoyant Life Sciences Sector Emerges Stronger
As we bid farewell to another eventful year in the world of life sciences, it’s time to look back at the whirlwind of advancements and changes that have shaped the industry in 2023. Back in January this year, we interacted with leaders from various market segments who shared their insights into what the year held for their particular spheres. Let’s recap the 2023 predictions and find out if they panned out as predicted.

Addressing Diabetes-related  complications 
Southeast Asia is currently home to 90 million adults diagnosed with diabetes, and this number is expected to reach 113 million by 2030, according to the International Diabetes Federation (IDF) Diabetes Atlas 2022. Out of these 90 million, 46 million remain undiagnosed. The delayed diagnosis of diabetes leads to prolonged periods of uncontrolled  hyperglycemia, resulting in severe diabetes related complications, such as diabetic retinopathy (eye problems), diabetic foot ulcers (DFU), diabetic nephropathy (kidney problems), and cardiovascular diseases. The vast number of people affected by diabetes, including many who are undiagnosed or at risk, presents a massive market for innovative treatments and preventive solutions. New technologies and novel treatment approaches offer hope for better prevention and management of these diabetes-related complications.

Big Pharma Sets Sights on Middle East
The Middle East, traditionally renowned for its prominence in the travel and oil and gas industries, is shifting its focus towards the life sciences sector. The region is actively forging numerous partnerships, initiatives, and programmes, and spending billions to establish itself as a major hub for life sciences. As the population of the region continues to grow and age, there is a clear and growing demand for locally manufactured medical treatments and products. Big pharma players are also making substantial inroads into the Middle East, with the Kingdom of Saudi Arabia (KSA), 
Qatar, and the United Arab Emirates (UAE) leading the way in these regional efforts. Areas such as rare diseases, genomics, personalised medicines, and pharmaceutical manufacturing have emerged as hotspots in the Middle East. Let’s delve deeper 
into the region’s endeavours to become a biotech powerhouse.

Multipronged Approach Against Alzheimer’s Disease
In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.

TAIWAN BIOMED INDUSTRY EYES $32B 
Biomedicine is a top priority for Taiwan, with the government aiming to position the country as the leading hub for biomedical research and development in the Asia-Pacific region. By 2025, Taiwan aims to create 20 new medicines, introduce 80 high-value medical devices to the market, and elevate the biomedicine industry into a trillion-NT-dollar (approximately $32 billion) sector. The government has taken various initiatives, established biomedicines clusters and tweaked policies to achieve this goal. Has the effort paid off? How far has the country come to achieve its goals?

TECH-POWERED WAR ON AMR
The consistent increase in antimicrobial resistance (AMR) is threatening to undo many of the gains of modern medicine. The situation is particularly alarming in the Asia Pacific region, which could witness around 50 per cent of global annual AMR-related mortality by 2050. Around 62 per cent of antibiotics in the region are used without prescriptions, indicating inappropriate usage and significantly increasing
the risk of AMR strain emergence, according to a report from LEK Consulting Group. All this makes the region an epicentre of AMR and its consequences. In response to the growing threat, countries in the region have taken steps to tackle the AMR threat. These include a National Action Plan on AMR (NAP-AMR), antimicrobial stewardship efforts, diagnostics surveillance etc. However, the million-dollar
question is whether these steps will be effective and enough. Let’s find out.

TAPPING FULL POTENTIAL OF NANOPARTICLES
Nanoparticles are another powerful tool in the biotech industry’s arsenal for targeted drug delivery. Their extremely small size, measured in nanometres, makes them highly effective carriers for therapeutic agents. These miniature carriers can be customised to encase drugs, benefiting from their biocompatibility, controlled release capabilities, stability, and low toxicity. The precision offered by nanoparticles opens up a world of possibilities for treating various diseases, including infectious diseases, cancer, and neurological disorders. These tiny particles offer tremendous
potential for targeted drug delivery, enhanced therapeutic efficacy and precise disease targeting. Moreover, the global market for nanoparticle drug delivery is projected to grow significantly, reaching $123.6 billion by 2025, according to BCC Research. Let’s deep dive into the fascinating field of nanomedicines, advancements and challenges in nanoparticle drug delivery.

$15B Pharma R&D Spends ROCKS APAC
Earlier seen as a generic powerhouse, Asia is now an important hub for pharma R&D innovation. The total gross expenditure by major companies on R&D across the Asia Pacific region crossed the $15 billion mark (approx) in 2022. Oncology, neurology, and immunology continue to draw a significant chunk of this investment. BioSpectrum Asia examines how top pharma companies in the region are
allocating their R&D budgets and the impact of the ensuing R&D endeavours on the industry.

A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people. According to a latest report on malaria from the World Health Organisation (WHO), there were approximately 5.4 million cases and 9000 deaths in the region in 2021. The SEA region has nine countries where malaria is prevalent, and their contribution to the global burden of malaria cases is two per cent. India is the main contributor to the malaria cases in the region, accounting for 82.5 per cent of them, followed by Indonesia with 15.6 per cent, and Myanmar with 1.6 per cent. These three countries were responsible for almost all of the malaria cases in the region, making up 99.7 per cent of the total estimated cases. Governments, healthcare organisations, and communities are implementing innovative strategies, technologies, and programmes that can help curb the spread of malaria. Though these efforts were hampered because of COVID-19, in 2022, the WHO South-East Asia Region renewed its commitment to eliminate malaria by 2030, with countries pledging accelerated action and greater efforts at the sub-national and community levels. Other parts of Asia also progressed well. China was declared Malaria free in June 2021, after 70 years of fighting. In its fights against malaria, Asian countries have recently
announced significant investment including a $1.9 million investment in February 2023 by Japan’s GHIT Fund for the research and development of a new malaria drug, and a $1 million contribution by Singapore’s Ministry of Health to the Global Fund to fight AIDS, TB, and Malaria, announced in December 2022. While observing World Malaria day on April 25, let’s explore the current status of Asia’s malaria elimination efforts, highlighting the progress made and strategies needed for a malaria-free future.

HOW PLAUSIBLE IS ENDINGHOW PLAUSIBLE IS ENDING TB SCOURGE?
Tuberculosis (TB) has been the leading cause of death from a single infectious agent, ranking above HIV/AIDS for a long time. And, presently, Asia Pacific is right in the thick of it. South-eastern Asia (SEA) is home to 26 per cent of the world’s population with a 43 per cent burden of TB incidence, according to the World Health Organisation’s (WHO) global TB report 2021. Over the last three years, countries around the world, including in Asia and the Pacific, have faced double pandemics –COVID-19 and TB. Unfortunately, during this time, progress toward TB elimination stalled and, in some cases, reversed. COVID-19 made it harder for people to access TB diagnostics and care, eading to increases in cases and deaths since 2019. Four countries, India, Indonesia, the Philippines, and Myanmar accounted for most of the estimated increase in TB deaths, globally, in 2021. Not all is lost though. The countries in the region, especially India and Indonesia, have renewed their efforts to eliminate TB. India launched the TB Free India campaign – a plan to eliminate tuberculosis by 2025, five years ahead of the target set by the UN’s sustainable development goals. Indonesia received a $300 million loan from the World Bank to improve overage, quality and efficiency of TB response in the country. When observing World TB day this year on March 24, let’s take stock of the progress made by Asian countries in eliminating this dreaded disease and the way forward.

CANCER THERAPEUTICS GAINING GROUND IN APAC
Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry. Not surprising that pharma companies continue to dedicate a significant part of their R&D budget for Oncology. Cancer medicine spending rose to $185 billion globally in 2021 and is expected to reach more than $300 billion by 2026, as per IQVIA. China’s oncology spending now exceeds the rest of emerging countries and is driven by expanded access to new therapies
and offset by lower prices. Chinese and other Asian cancer drug developers are at the forefront of driving innovation in this space. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The next wave of innovations making headlines in the cancer space include immunotherapies, vaccines, CAR-T therapies, PD-1/L1 inhibitors, light-activated drugs etc. Many drug makers in Asia are investing in new science and hope to develop the next holy grail in oncology. Let’s take a deep
dive into the status of cancer drug research and development in the Asia Pacific (APAC).

Life Sciences Trends to Watch for in 2023
The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn’t been impervious to the major financial upheavals either. Yes, it’s the Pandemic and Post-Pandemic world that’s been influencing people from all walks of life and industries, alike. Buzzwords notwithstanding, we do have to thank the pandemic situation that forced all stakeholders to innovate and pool the best and brightest resources to keep the Life Sciences industry thriving. While all other industries either lost steam in their growth plans, pharma boomed, not unlike the Phoenix rising from the ashes. It is this streak of resilience and growth that we want industry insiders to comment on. With curtains down for 2022, it’s time to look to the new year without the trepidation of the looming ‘Great Reset’. On an upbeat note, BioSpectrum brings you 23 trends and projections for 2023 that could reshape and influence our collective future.

BioSpectrum Asia Excellence Awards 2022 
Asia has, indeed, become the new hub for potential growth and innovation, with no signs of losing steam. To appreciate the Asian companies and individuals for their commendable performance and achievements during Calendar Year (CY) 2021, BioSpectrum Asia Excellence Awards 2022 ceremony was held at Lavender Ball Room, Hotel Fort Canning in Singapore on December 2, 2022. These awards are an extension to observe and highlight the winners in the long battle to tackle the world’s emerging health problems and find solutions. Since 2020 and 2021 were majorly affected by COVID-19, we saw the industry players relentlessly working towards developing novel solutions in the form of diagnostic tests, vaccines, monoclonal antibodies, drugs etc. to fight the emergency.

Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,
according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.

Can Technology Efface SLEEP DISORDERS?
The world is wide awake. Sleep disorders are on the rise globally and the Asia Pacific is no
different. There are numerous studies documenting how sleep loss is rampant and becoming an epidemic. Approximately 45 per cent of people worldwide don’t get enough sleep. Asians have the shortest average sleep time, according to researchers from Flinders University, Australia. To combat these, firms are now turning to technology. The emergence of wearables, smart devices, trackers, and patches has made widespread remote sleep monitoring possible. Insights gained from the data collected by these devices are used to improve understanding of sleep and create preventative sleep loss strategies. Let’s look at how healthcare firms are trying to unlock the science of sleep disorders diagnosis and treatment by leveraging new tech.

INCUBATORS IGNITING BIOSCIENCE ECOSYSTEM
Incubators and accelerators are driving small and medium enterprises (SMEs) in Asia
through the development of novel therapeutics and encouraging innovations and
commercialisation. Biotechnology incubators provide a stimulating environment that
attracts investors, talent, and companies to collaborate on research, thereby fostering
industry growth. While the appetite for laboratory space is constantly growing among
biotech ventures, countries in the Asia Pacific (APAC) region are actively investing
to construct life science hubs that foster innovation strategies and strengthen R&D
capabilities. Let’s explore prominent startup incubators and accelerators in key APAC
economies that are cultivating biotech innovations to create unicorns.

Keeping Pace with MUTATING VIRUSES 
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the
challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.

HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?
A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract evelopment and manufacturing organisations (CDMOs) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let’s navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system

BioSpectrum Asia  Cover - December 2024 Edition

December 2024

BioSpectrum Asia  - December 2024

BioSpectrum Asia  Cover - BioSpectrum Asia Nov 2024 Edition

BioSpectrum Asia Nov 2024

BioSpectrum Asia  - BioSpectrum Asia Nov 2024

BioSpectrum Asia  Cover - October 2024 Edition

October 2024

BioSpectrum Asia  - October 2024

BioSpectrum Asia  Cover - September 2024 Edition

September 2024

BioSpectrum Asia  - September 2024

BioSpectrum Asia  Cover - August 2024 Edition

August 2024

BioSpectrum Asia  - August 2024

BioSpectrum Asia  Cover - July 2024 Edition

July 2024

BioSpectrum Asia  - July 2024

BioSpectrum Asia  Cover - June 2024 Edition

June 2024

BioSpectrum Asia  - June 2024

BioSpectrum Asia  Cover - May 2024 Edition

May 2024

BioSpectrum Asia  - May 2024

BioSpectrum Asia  Cover - April 2024 Edition

April 2024

BioSpectrum Asia  - April 2024

BioSpectrum Asia  Cover - March 2024 Edition

March 2024

BioSpectrum Asia  - March 2024

BioSpectrum Asia  Cover - BioSpectrum Asia Feb 2024 Edition

BioSpectrum Asia Feb 2024

BioSpectrum Asia  - BioSpectrum Asia Feb 2024

BioSpectrum Asia  Cover - BioSpectrum Asia January 2024 Edition

BioSpectrum Asia January 2024

BioSpectrum Asia  - BioSpectrum Asia January 2024

BioSpectrum Asia  Cover - December 2023 Edition

December 2023

BioSpectrum Asia  - December 2023

BioSpectrum Asia  Cover - November 2023 Edition

November 2023

BioSpectrum Asia  - November 2023

BioSpectrum Asia  Cover - October  2023 Edition

October  2023

BioSpectrum Asia  - October  2023

BioSpectrum Asia  Cover - September 2023 Edition

September 2023

BioSpectrum Asia  - September 2023

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

1. Magzter.com'un, uygulamanın ve hizmetlerinin kullanımının riskinin tamamen size ait olduğunu kabul etmektesiniz. Ne Magzter.com, ne ortakları, ne çalışanları ne de üçüncü taraf içerik sağlayıcılar, hizmetin tamamen kesintisiz veya hatasız olacağını veya kötü niyetli faaliyetlere karşı kusursuz olacağını garanti etmez. Web sitesi veya ürün tarafından beklendiği veya vaat edildiği gibi kesin sonuçları alacağınızı da garanti etmezler.

11. HİZMET VE TÜM YAYINLAR 'OLDUĞU GİBİ' VE 'MEVCUT OLDUĞU GİBİ' TEMELİNDE SUNULUR. MAGZTER, İŞTİRAKLERİ, TEDARİKÇİLERİ, LİSANS VERENLER VE TEMSİLCİLERİ, SATILABİLİRLİK, BELİRLİ BİR AMACA UYGUNLUK VE İHLAL ETMEME İLE İLGİLİ ZIMNİ GARANTİLER DAHİL ANCAK BUNLARLA SINIRLI OLMAMAK ÜZERE, AÇIK VEYA ZIMNİ HER TÜR GARANTİYİ AÇIKÇA REDDEDER. YUKARIDA BELİRTİLENLERİ SINIRLAMAKSIZIN, MAGZTER NE BAĞLI KURULUŞLARI, TEDARİKÇİLERİ, LİSANS VERENLER VEYA TEMSİLCİLERİ (I) HİZMETİN GEREKSİNİMLERİNİZİ KARŞILAYACAĞINA, (II) HİZMETİN KESİNTİSİZ, ZAMANINDA, GÜVENLİ VEYA HATASIZ OLACAĞINA, ( III) HİZMETİN KULLANIMINDAN ELDE EDİLECEK VEYA YAYINLARDA BULUNABİLECEK BİLGİLERİN DOĞRU VEYA GÜVENİLİR OLACAĞI VEYA (IV) HERHANGİ BİR YAYININ VEYA HİZMETİN KALİTESİ BEKLENTİLERİNİZİ KARŞILAYACAKTIR. GÜVENİLİR İNTERNET BAĞLANTISI VE CİHAZINIZI SAĞLAMAK VE SÜRDÜRMEKTEN YALNIZCA SİZ SORUMLUSUNUZ. MAGZTER, İÇERİĞİ İNDİREMEZSENİZDEN SORUMLU DEĞİLDİR. HİZMETİN KULLANIMIYLA İNDİRİLEN VEYA BAŞKA BİR ŞEKİLDE ELDE EDİLEN HERHANGİ BİR MALZEME, KENDİ TAKDİRİNİZDE VE RİSKİ SİZE AİTTİR VE BİLGİSAYAR SİSTEMİNİZDE VEYA MOBİL CİHAZINIZDA BU TÜR MATERYALİN İNDİRİLMESİNDEN KAYNAKLANAN HERHANGİ BİR HASARDAN VEYA VERİ KAYBINDAN YALNIZCA SİZ SORUMLU OLURSUNUZ. MAGZTER'DEN VEYA HİZMET ARACILIĞIYLA VEYA HİZMETTEN ELDE ETTİĞİNİZ SÖZLÜ VEYA YAZILI HİÇBİR TAVSİYE VEYA BİLGİ HERHANGİ BİR GARANTİ OLUŞTURMAZ.

2. Bu bilgileri doğru, doğru, güncel ve eksiksiz tutmak için koruyacak ve derhal güncelleyeceksiniz. Hesabınızın ve parolanızın gizliliğini korumaktan ve bilgisayarınıza erişimi kısıtlamaktan siz sorumlusunuz ve tüm içerik ve hizmetlerin seçimi ve kullanımı da dahil olmak üzere hesabınız altında gerçekleşen tüm faaliyetlerin sorumluluğunu kabul ediyorsunuz.

3. Magzter.com veya web sitesi ve uygulamadaki içeriğin oluşturulması, üretilmesi ve dağıtılmasında yer alan herhangi bir kişi veya kuruluş veya üçüncü taraf, aşağıdakiler dahil ve bunlarla sınırlı olmamak üzere hiçbir zarardan sözleşmede veya yasal olarak sorumlu tutulamaz: Magzter.com'u kullanırken veya kullanırken maruz kaldığınız doğrudan, dolaylı, tesadüfi, özel ve sonuç olarak ortaya çıkan. Web sitesine kayıt olarak veya uygulamayı indirerek, bu bölümde belirtilen hükümlerin web sitesi ve uygulamadaki tüm kullanım ve içerikler için geçerli olacağını kabul etmektesiniz.

3. Burada yayınlanan her şey Magzter'in veya lisans verenlerinin mülkiyetinde olduğundan, Magzter'in önceden yazılı veya yetkili izni olmaksızın, Magzter'den alınan hiçbir içeriği değiştirmemeli, kopyalamamalı, dağıtmamalı veya satmamalısınız. Bu tür yetkisiz kullanım, telif hakkı ve ticari marka yasaları dahil olmak üzere yürürlükteki yasaları da ihlal edebileceğinden, Magzter bunları kesinlikle yasaklar ve bu tür yasa dışı faaliyetlerin kanıtlanması veya tespit edilmesi durumunda erişiminizi ve hesabınızı sonlandırır. Bu yetkisiz faaliyetlerden kaynaklanan zararlardan da sorumlu olmalısınız. Yayının yasal sahibinin izin verdiği durumlar dışında, Hizmet aracılığıyla erişilen Yayınları indirerek herhangi bir mülkiyet hakkı elde etmediğinizi kabul edersiniz. Telif hakkı yasasının açıkça gerektirdiği veya Hizmetin özelliklerinin izin verdiği durumlar dışında, değiştiremez, tersine mühendislik uygulayamaz, yayınlayamaz, iletemez, görüntüleyemez, devir veya satışına katılamaz, türev çalışmalar oluşturamaz veya herhangi bir şekilde ticari olarak kullanamaz veya sağlayamazsınız. Magzter'in ve söz konusu içeriğin sahibinin açık izni olmaksızın Uygulamanın, Yayınların veya bunların herhangi bir bölümünün içeriğinin üçüncü taraflarca paylaşılması. Size, Magzter veya Magzter'e lisans verenlerin fikri mülkiyetine ilişkin açık veya zımni herhangi bir lisans vermiyoruz.

5. Magzter.com'un diğer kullanıcılara veya üçüncü taraflara veya içeriklerine yönelik herhangi bir iftira niteliğinde veya saldırgan veya yasa dışı davranıştan sorumlu olmadığını ve bunlardan kaynaklanan yaralanma riskinin tamamen size ait olduğunu özellikle kabul etmektesiniz.

 7. Magzter, bu hüküm ve koşullara ve Magzter tarafından belirlenen diğer işletim kurallarına uyup uymadığınızı belirlemek amacıyla sizin tarafınızdan yayınlanan ve girilen içeriği izleme hakkını saklı tutar. Magzter, içerikle ilgili kararlar alma ve bunları kendi isteğiyle silme hakkına sahiptir.

8. Magzter, Yayınların yayıncısı DEĞİLDİR, distribütörüdür ve bu nedenle Magzter'in, dergilerde temsil edilen görüşler, tavsiyeler, beyanlar, hizmetler, teklifler vb. dahil olmak üzere içerik üzerinde herhangi bir editoryal kontrolü yoktur. Bu nedenle Magzter, resmi sıfatlarıyla hareket eden yetkili Magzter çalışanları dışında herhangi biri tarafından sağlanan veya hizmet aracılığıyla sunulan herhangi bir bilgi veya olgunun doğruluğu veya güvenilirliği konusunda sorumluluk almayacaktır. Buna göre, Yayınlar üzerinde herhangi bir editoryal kontrolümüz yoktur. Hizmet tarafından sunulan Yayınlarda yapılanlar da dahil olmak üzere, üçüncü şahıslar tarafından ifade edilen veya kullanıma sunulan her türlü görüş, tavsiye, beyan, hizmet, teklif veya diğer bilgi veya içerik, ilgili yazar(lar)a veya yayıncı(lar)a aittir ve üçüncü taraflara ait değildir. Magzter. Magzter, Hizmet aracılığıyla veya Yayınlardan elde edilen bilgilere güvenmenizden kaynaklanan herhangi bir kayıp veya hasardan sorumlu olmayacaktır. Hizmet, diğer İnternet sitelerine ve üçüncü taraf kaynaklara bağlantılar içerebilir ve Magzter, bu tür bağlantılı sitelerde bulunan iletişim veya materyaller için herhangi bir sorumluluk veya yükümlülük kabul etmez. Bu bağlantılar yalnızca size kolaylık sağlamak için sağlanmıştır. Üçüncü taraf bir siteyi ziyaret ettiğinizde veya bu site aracılığıyla sipariş verdiğinizde geçerli olabilecek tüm hüküm ve koşulları anlamaktan yalnızca siz sorumlusunuz.

 Platformumuzdaki bağlantısı da dahil olmak üzere sakıncalı içeriğin ayrıntıları

 En sevdiğiniz kitapları indirin ve çevrimdışı, her zaman ve her yerde okuyun

 Sevdiklerinize anında bir Magzter Hediye Kartı hediye edin ve onlara en çok satan binlerce başlık arasından en sevdikleri dergi ve gazeteleri okuma özgürlüğü verin.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

Bir Magzter Hediye Kartı ile sevdiklerine anında hediye et ve onlara {{magCount}} en iyi satan uluslararası isimden favori dergilerini okuma özgürlüğü ver.

Girish Ramdas, küresel dijital yayıncılık işinde dalgalar yaratan New York merkezli bir girişim olan Magzter'in Kurucu Ortağı ve CEO'sudur. Magzter, kurulduğu 2011 yılından bu yana dünya çapında 4.500'den fazla yayıncıdan 1000'lerce dergi, gazete ve kitapla 150'den fazla ülkeden 80 milyon kullanıcıyı aştı. Basılı, mobil ve Web geliştirme dahil olmak üzere platformlar arası yayıncılıkta 25 yıldan fazla deneyime sahiptir. Bu süre zarfında, üç başarılı start-up şirketi kurdu ve yönetti. Dergi şirketlerinin dijitalleşmesini sağladı ve dijital dünyadaki içeriklerinden para kazanmalarına yardımcı oldu. Girish'in çevrimiçi, mobil ve yayıncılık ekosistemlerindeki derin sektör deneyimi, onu dünya çapındaki platformlarda dijital içerik edinme, pazarlama ve paraya çevirme konusunda uzman yaptı.

 Platformumuzda sakıncalı herhangi bir içerikle karşılaşmanız durumunda, endişelerinizi gidermek için bir şikayet giderme politikası oluşturduk.

Magzter Inc. (“Şirket”, “biz”, “bize” veya “bizim”) kişisel bilgilerinizin nasıl kullanıldığını ve paylaşıldığını önemsediğinizi bilir. Gizlilik uygulamalarımız hakkında daha fazla bilgi edinmek için lütfen aşağıdaki gizlilik politikasını (“Politika”) okuyun.Şirket tarafından işletilen web sitelerinden herhangi birini ve bunların alt alanlarını ziyaret ederek veya mobil uygulamalarımızdan ve diğer içerik dağıtım yöntemlerinden herhangi birini kullanarak(toplu olarak “Hizmet“), belirtilen uygulamaları ve politikaları kabul ettiğinizi kabul edersiniz.bu Politikada yer alır ve bilgilerinizi aşağıdaki şekillerde toplayacağımıza, kullanacağımıza ve paylaşacağımıza işbu vesile ile izin vermiş olursunuz.

Magzter Inc., kurulduğu 2011 yılından bu yana 80 milyondan fazla kullanıcısı ve 40'tan fazla kategoride ve 60'tan fazla dilde binlerce dergi ve gazeteyle dünyanın en büyük ve en hızlı büyüyen self servis, platformlar arası dijital gazete bayisidir. Merkezi New York'ta bulunan Magzter'in Amsterdam, Londra, Mexico City, Chennai, Mumbai, Yeni Delhi, Bengaluru, Singapur'da yerel varlığı bulunmaktadır ve yakında diğer ülkelere de yayılacaktır. Haziran 2011'de küresel girişimciler Girish Ramdas ve Vijay Radhakrishnan tarafından kurulan Magzter, dünyanın dört bir yanındaki dergi ve gazete yayıncılarının kitaplarının dijital baskılarını oluşturup küresel tüketicilere ulaştırmasına olanak tanıyor.

 Magzter, kullanıcılarımız için güvenli ve emniyetli bir platform sağlamaya kendini adamıştır. Lütfen Magzter'in yalnızca yayıncıların içeriklerini dağıtmaları için bir platform olduğunu unutmayın. Platformumuzda yayınlanan içeriği kontrol etmiyor veya desteklemiyoruz. Yayıncılarımızın eylemlerinden veya içeriklerinden sorumlu tutulamayız.

Magzter, haklarını ihlal eden herhangi bir içerik veya içeriğin bir kısmı nedeniyle zarar gören veya masrafa maruz kalan tarafları tazmin etmekten sorumlu değildir. Magzter, üçüncü şahısların haklarını ihlal eden herhangi bir içerikten veya içeriğin bir kısmından kaynaklanan herhangi bir hak ihlali nedeniyle hukuk mahkemesinde herhangi bir yasal işlem başlatmakla yükümlü değildir.

Magzter, dijital okuyuculara aylık abonelik ücreti karşılığında 8.000'den fazla dergi ve gazeteye sınırsız erişim sağlayan Magzter GOLD adlı dünyanın en büyük All- You - Can - Read abonelik hizmetini sunuyor.Magzter ayrıca, akıllı telefon ve küçük ekranlı mobil kullanıcıların dergi içeriğinin keyfini çıkarması gerektiği gibi, makale metniyle keyfini çıkarmasını sağlayan, uygulamaları için ezber bozan ezRead 2.0 özelliği ile dünyadaki en fazla sayıda hikayeye sahiptir.okunması kolay ve buna çarpıcı videolar ve yüksek çözünürlüklü fotoğraflar eşlik ediyor.

İsim

İçeriğini Magzter'da yayınlamakla ilgili herhangi bir yardıma ihtiyacın varsa lütfen bu formu doldur

 Magzter'den önce Dot Com Infoway (DCI) ve Galatta Media'nın Başkanlığını yapmıştır. Görevleri arasında stratejik pazarlama, ortaklık geliştirme ve küresel olarak içerikten para kazanma yer alıyordu. DCI, 2000'de 3 kişilik küçük bir ekipten 2011'de 300'e yükseldi ve dünya çapındaki müşterileri için web, yazılım ve uygulama geliştirme ile ilgileniyordu.

Hizmetimizi başlattığımızdan beri Magzter, müşterilerimize mümkün olan en yüksek gazete bayii teknolojisini ve hizmetini sunmak için kendini küresel kuruluşlarla ortak olmaya adadı. İster müşteri veritabanınıza dergi aboneliği sunma amacını güdün ya da isterse sadece daha fazla öğrenmeyi amaçlayın, Magzter kendisini ticaretinizin büyümesine yardım etmek için adadı. Daha fazla öğrenmek için lütfen aşağıdaki soru formunu doldur:

{{trialPackText}} İÇİN ÜCRETSİZ DENE

 Orijinal DMCA Bildirimini gönderen taraf, Karşı Bildiriminizin kopyasını aldıktan sonra on iş günü içinde size karşı bir dava açmazsa, DMCA, kaldırılan içeriği geri yüklememize izin verir.

Bu Politika, Şirketin kişisel olarak tanımlanabilir bilgileri(“Kişisel Bilgiler“) ve siz ve Hizmete eriştiğinizde Şirketin topladığı bilgisayarınız veya cihazınız hakkında diğer bilgileri nasıl ele aldığını kapsar.Aşağıda daha ayrıntılı olarak açıklandığı şekilde sizden Kişisel Bilgiler toplayabiliriz ve bu Kişisel Bilgileri, ürünlerimizi, hizmetlerimizi, içeriğimizi ve reklamlarımızı kişiselleştirmek, sağlamak ve iyileştirmek ve size izin vermek de dahil olmak üzere Hizmetlerimizle bağlantılı olarak dahili olarak kullanırız.kullanıcı hesabı ve profili oluşturmak, sizinle iletişime geçmek, belirli ürün ve hizmetlere yönelik taleplerinizi yerine getirmek ve Hizmetleri nasıl kullandığınızı analiz etmek.Belirli durumlarda, bazı Kişisel Bilgileri üçüncü taraflarla da paylaşabiliriz, ancak yalnızca 4. maddede açıklandığı şekilde.

Bu başlık, Magzter GOLD aboneliğinize dahildir

 İçeriğin kalitesini analiz etmek ve yayıncılara uygun geri bildirim sağlamak

 Sakıncalı içerikle ilgili şikayetleri ele almak için bir Şikayet Görevlisi görevlendirdik.

 Sakıncalı içerikle ilgili herhangi bir şikayetin, yukarıda belirtilen e-posta adresine e-posta yoluyla Şikayet Görevlisine gönderilmesini talep ediyoruz. Şikayette bulunurken aşağıdaki bilgileri de vermenizi rica ederiz.

ve size çeşitli dergi, kitap, haber ve dergi ve yayınla ilgili içeriği (toplu olarak 'Yayınlar' olarak bilinir) sipariş etme, abone olma ve teslimatını alma ve Yayınların bu dijital sürümlerinin size teslim edilmesini sağlayan Uygulama

C.Kişiselleştirilmiş önerilerde bulunmak için uygulamayı kullanımınızla ilgili bilgileri de topluyoruz.Üçüncü taraf hesap kimlik bilgilerinizi bize sağlarsanız, bu tür aktarımlara izin verirseniz, bu hesaplardaki bazı içerik ve / veya bilgilerin(“Üçüncü Taraf Hesap Bilgileri“) bizimle olan hesabınıza aktarılabileceğini ve bu Üçüncü Taraf Hesabını anlamış olursunuz.Hizmete iletilen bilgiler bu Politika kapsamındadır.

 F. Topladığımız Kişisel Bilgiler, isteklerinize yanıt vermemize, ürünlerimizi ve hizmetlerimizi iyileştirmemize, gördüğünüz reklamları ve içeriği özelleştirmemize ve sizinle yeni ürünler hakkında iletişim kurmamıza olanak tanır.

kurulduğu 2011'den bu yana 85 milyondan fazla kullanıcısı ve 40'tan fazla kategoride ve 60'tan fazla dilde binlerce dergi ve gazeteyle dünyanın en büyük ve en hızlı büyüyen self servis, platformlar arası dijital gazete bayisidir. Merkezi New York'ta bulunan Magzter'in Amsterdam, Londra, Mexico City, Chennai, Mumbai, Yeni Delhi, Bengaluru, Singapur'da yerel varlığı bulunmaktadır ve yakında diğer ülkelere de yayılacaktır. Haziran 2011'de küresel girişimciler Girish Ramdas ve Vijay Radhakrishnan tarafından kurulan Magzter, dünyanın dört bir yanındaki dergi ve gazete yayıncılarının kitaplarının dijital baskılarını oluşturup küresel tüketicilere ulaştırmasına olanak tanıyor.

 N. Kullanıcıların Kullanım Koşullarımıza uymasını sağlamak için kullanım bilgilerini de kullanacağız. Örneğin, bir kullanıcının kullanım bilgileri, bir kullanıcının bir dergiyi veya başka bir içeriği yalnızca izin verilen sayıda veya izin verilen sayıda cihaza indirdiğini doğrulamamıza yardımcı olur.

 dijital okuyuculara aylık abonelik ücreti karşılığında 8.000'den fazla dergi ve gazeteye sınırsız erişim sağlar. Magzter ayrıca, akıllı telefon ve küçük ekranlı mobil kullanıcıların dergi içeriğinin keyfini çıkarması gerektiği gibi, makale metniyle keyfini çıkarmasını sağlayan, uygulamaları için ezber bozan ezRead 2.0 özelliği ile dünyadaki en fazla sayıda hikayeye sahiptir. okunması kolay ve buna çarpıcı videolar ve yüksek çözünürlüklü fotoğraflar eşlik ediyor.

BioSpectrum Asia - June 2018

BioSpectrum Asia - June 2018

Bu konuda

BioSpectrum Asia Magazine Description: